Compare Divis Laboratories with Biocon - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs BIOCON - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES BIOCON DIVIS LABORATORIES/
BIOCON
 
P/E (TTM) x 57.6 31.5 182.9% View Chart
P/BV x 15.4 3.7 410.5% View Chart
Dividend Yield % 0.4 0.3 151.3%  

Financials

 DIVIS LABORATORIES   BIOCON
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
BIOCON
Mar-19
DIVIS LABORATORIES/
BIOCON
5-Yr Chart
Click to enlarge
High Rs1,639707 231.8%   
Low Rs1,115554 201.3%   
Sales per share (Unadj.) Rs186.391.9 202.7%  
Earnings per share (Unadj.) Rs51.016.7 304.9%  
Cash flow per share (Unadj.) Rs57.324.2 237.1%  
Dividends per share (Unadj.) Rs16.001.00 1,600.0%  
Dividend yield (eoy) %1.20.2 732.6%  
Book value per share (Unadj.) Rs261.8101.6 257.6%  
Shares outstanding (eoy) m265.47600.00 44.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.46.9 107.7%   
Avg P/E ratio x27.037.7 71.6%  
P/CF ratio (eoy) x24.026.1 92.1%  
Price / Book Value ratio x5.36.2 84.8%  
Dividend payout %31.46.0 524.7%   
Avg Mkt Cap Rs m365,592378,330 96.6%   
No. of employees `00011.86.1 193.2%   
Total wages/salary Rs m5,42311,653 46.5%   
Avg. sales/employee Rs Th4,175.18,994.3 46.4%   
Avg. wages/employee Rs Th457.71,900.7 24.1%   
Avg. net profit/employee Rs Th1,141.81,635.3 69.8%   
INCOME DATA
Net Sales Rs m49,46355,144 89.7%  
Other income Rs m1,5561,444 107.8%   
Total revenues Rs m51,01956,588 90.2%   
Gross profit Rs m18,71815,883 117.9%  
Depreciation Rs m1,6894,478 37.7%   
Interest Rs m35709 4.9%   
Profit before tax Rs m18,55112,140 152.8%   
Minority Interest Rs m09 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,0232,123 236.6%   
Profit after tax Rs m13,52710,026 134.9%  
Gross profit margin %37.828.8 131.4%  
Effective tax rate %27.117.5 154.8%   
Net profit margin %27.318.2 150.4%  
BALANCE SHEET DATA
Current assets Rs m46,50148,228 96.4%   
Current liabilities Rs m8,46830,376 27.9%   
Net working cap to sales %76.932.4 237.5%  
Current ratio x5.51.6 345.9%  
Inventory Days Days13168 191.5%  
Debtors Days Days8686 100.4%  
Net fixed assets Rs m25,79764,130 40.2%   
Share capital Rs m5313,000 17.7%   
"Free" reserves Rs m68,96257,980 118.9%   
Net worth Rs m69,49360,980 114.0%   
Long term debt Rs m015,766 0.0%   
Total assets Rs m80,383121,924 65.9%  
Interest coverage x531.018.1 2,930.1%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.60.5 136.1%   
Return on assets %16.98.8 191.6%  
Return on equity %19.516.4 118.4%  
Return on capital %26.716.8 159.6%  
Exports to sales %028.1 0.0%   
Imports to sales %24.618.9 130.7%   
Exports (fob) Rs mNA15,506 0.0%   
Imports (cif) Rs m12,18710,399 117.2%   
Fx inflow Rs m41,23815,506 265.9%   
Fx outflow Rs m12,40510,399 119.3%   
Net fx Rs m28,8335,107 564.6%   
CASH FLOW
From Operations Rs m9,54311,546 82.7%  
From Investments Rs m-6,854-7,138 96.0%  
From Financial Activity Rs m-2,459-2,417 101.8%  
Net Cashflow Rs m2302,103 10.9%  

Share Holding

Indian Promoters % 52.0 40.4 128.7%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 11.8 8.4 140.5%  
FIIs % 19.0 10.7 177.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 19.9 86.4%  
Shareholders   31,796 109,995 28.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   FRESENIUS KABI ONCO.  ELDER PHARMA  SUVEN LIFE SCIENCES  ALKEM LABORATORIES  WOCKHARDT  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


May 7, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS